Bitopertin is at least 4 years away from marketing approval, if it actually manages to traverse P2 and P3. Presuming it actually makes it that far, it won't get expedited review as there is a therapy already approved (Scenesse).
Bitopertin is at least 4 years away from marketing approval, if...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.44 |
Change
-1.070(6.90%) |
Mkt cap ! $718.6M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $3.919M | 267.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8 | $14.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.45 | 187 | 9 |
View Market Depth
| Last trade - 15.49pm 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |